Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes.

6605 Background: At 18 months (mos) of follow-up in the randomized phase 3 DASISION trial of dasatinib vs imatinib (IM) in newly diagnosed CML-CP, dasatinib continued to show superior efficacy and acceptable safety/tolerability (Shah et al. Blood 2010; 116: abs 206). Although fluid retention was more frequent with IM, pleural effusion was only seen with dasatinib. Here, pts with drug-related pleural effusion are analyzed retrospectively and management methods are discussed. Methods: In DASISION, pts received dasatinib 100 mg once daily (QD) or IM 400 mg QD. Pts with baseline pleural effusion were excluded. Chest x-rays were performed at baseline and after 6 mos, or more frequently if indicated clinically. Pleural effusions were graded according to CTCAE v3.0 criteria. Results: After 18 mos median treatment duration, 31/258 dasatinib-treated pts had a pleural effusion (12%; 3% grade 1, 9% grade 2, <1% grade 3). Pts with pleural effusion were older (median age 59 vs 44 yrs). In pts with (n=31) vs without (n...